Anticoagulants and Immunosuppressives in Behçet’s Syndrome
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis
By Arisa Chuklin, Thita Joy Chiasakul, and Noppacharn Uaprasert
• Context: Behçet’s syndrome is a systemic vasculitis often complicated by venous or arterial thrombosis, yet the optimal role of anticoagulation remains uncertain.
• Study: Across 20 studies (315 patients with disaggregated data), this meta-analysis compared relapse rates under immunosuppressives, anticoagulants, or both.
• Findings: Combination therapy markedly reduced thrombosis relapse (17.7%) versus immunosuppressives alone (43.7%) or anticoagulants alone (54.9%), supporting a dual-modality approach for vascular Behçet’s.”
Title: Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis
Authors: Arisa Chuklin, Thita Chiasakul, Noppacharn Uaprasert
Read the article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice
-
Jul 2, 2026, 21:49Lee Peter Bee: The Plastic in Your Blood Is Sabotaging Your Stem Cells
-
Jul 2, 2026, 21:49Atef Ahmed: The Lethal Triad and Damage Control Philosophy
-
Jul 2, 2026, 20:48João L. Carapinha: How Does HYMPAVZI Simplify Hemophilia Management for Patients?
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story